Market Overview:
The global peptide antibiotics market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of antibiotic-resistant infections, rising demand for peptide antibiotics from the food industry, and growing investments by pharmaceutical companies in R&D for peptide antibiotics. Based on type, the global peptide antibiotics market can be segmented into ribosomal synthesized peptide antibiotics and non-ribosomally synthesized peptide antibiotics. Ribosomal synthesized peptides are produced through translation of mRNA molecules present in cells, while non-ribosomally synthesized peptides are produced without involving ribosomes. Non-ribosomally synthesized antimicrobials are more potent than their ribosomal counterparts and have a longer half-life. They are also less susceptible to degradation by enzymes present in bacteria, which makes them ideal candidates for development as antibacterial agents. Based on application, the global Peptide Antibiotics Market can be segmented into pharma & healthcare sector, food industry sector, commodities sector and other sectors such as cosmetics & personal care products etcetera).
Product Definition:
A peptide antibiotic is a small molecule composed of two or more amino acids linked by peptide bonds. Peptide antibiotics are important because they can penetrate the cell wall of Gram-negative bacteria and disrupt the cell membrane, leading to bacterial death.
Ribosomal Synthesized Peptide Antibiotics:
Ribosomal synthesized peptide antibiotics are the peptides which are formed by the enzymatic hydrolysis of a protein. The antibiotic properties of these products can be attributed to their ability to bind and inhibit ribonucleic acid (RNA) polymerase, thus preventing the synthesis of bacterial cells. These products have been found effective in treating infections caused by Escherichia coli, Salmonella spp.
Non-Ribosomally Synthesized Peptide Antibiotics:
Non-ribosomally synthesized peptide antibiotics are the antibiotic molecules that are not made by a ribosome. They do not fit into the typical antibiotic class as they are smaller in size and have fewer amino acids than typical antibiotics such as tetracycline, doxycycline or cephalosporin. However, they can be used to treat infections caused by some bacteria including E.
Application Insights:
The other application segment includes peptide antibiotics for use in agriculture and food production. The growing demand for antibiotic-free meat, dairy products, and eggs is expected to drive the growth of this segment over the forecast period. Other applications include disease treatment through injection such as streptococcal infections, staphylococcal infections including Staphylococcus aureus infection in humans and animals, Haemophilus influenzae type b (Hib) meningitis & sepsis, bacterial pneumonia among others.
Peptide antibiotics have various advantages over conventional classes of antibiotics such as penicillin G & C which are derived from natural sources that may vary from year to year due to mutations caused in Penicillium fungi during cultivation; these factors make it difficult for manufacturers to maintain constant product levels throughout the year.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of peptide antibiotic manufacturers and high demand for antibiotics. The region is expected to maintain its dominance over the forecast period due to increasing R&D investments by companies and universities, rising awareness about peptide antibiotics, growing healthcare spending by government & other organizations, and favorable reimbursement policies.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to factors such as improving economic conditions in emerging countries like India & China; increase in disposable income; rise in consumerism; expansion of retail sector including supermarkets & hypermarkets; increase medical tourism especially from developing economies like India, China & Thailand etc. These aforementioned factors are anticipated boost product demand across various applications thereby driving regional growth.
Growth Factors:
- Increasing incidence of antibiotic-resistant infections: The increasing incidence of antibiotic-resistant infections is a major growth driver for the peptide antibiotics market. According to the Centers for Disease Control and Prevention (CDC), more than two million people in the U.S. are infected with antibiotic-resistant bacteria every year, resulting in at least 23,000 deaths.
- Rising demand for novel antibiotics: The growing demand for novel antibiotics is another key growth driver for the peptide antibiotics market. With few new classes of antibiotics being developed in recent years, there is an urgent need for novel drugs that can combat drug-resistant pathogens. Peptide antibiotics offer a potential solution to this problem and are thus attracting increasing attention from pharmaceutical companies and researchers alike.
Scope Of The Report
Report Attributes
Report Details
Report Title
Peptide Antibiotics Market Research Report
By Type
Ribosomal Synthesized Peptide Antibiotics, Non-Ribosomally Synthesized Peptide Antibiotics
By Application
Pharma & Healthcare, Food Industry, Commodities, Other
By Companies
Pfizer, Novartis, GlaxoSmithKline, Eli Lilly, Theravance, Vicuron Pharmaceuticals, Savara Pharmaceuticals, AMP Therapeutics, Hospira, Kasten, Madam Therapeutics, Phosphagenics, Pacgen Life Science Corporation
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Peptide Antibiotics Market Report Segments:
The global Peptide Antibiotics market is segmented on the basis of:
Types
Ribosomal Synthesized Peptide Antibiotics, Non-Ribosomally Synthesized Peptide Antibiotics
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pharma & Healthcare, Food Industry, Commodities, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- GlaxoSmithKline
- Eli Lilly
- Theravance
- Vicuron Pharmaceuticals
- Savara Pharmaceuticals
- AMP Therapeutics
- Hospira
- Kasten
- Madam Therapeutics
- Phosphagenics
- Pacgen Life Science Corporation
Highlights of The Peptide Antibiotics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Ribosomal Synthesized Peptide Antibiotics
- Non-Ribosomally Synthesized Peptide Antibiotics
- By Application:
- Pharma & Healthcare
- Food Industry
- Commodities
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Peptide Antibiotics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Peptide antibiotics are a type of antibiotic that is made from a short peptide chain. Peptides are smaller than proteins and can pass through the cell membrane more easily. This makes peptide antibiotics more effective at killing bacteria than traditional antibiotics.
Some of the major companies in the peptide antibiotics market are Pfizer, Novartis, GlaxoSmithKline, Eli Lilly, Theravance, Vicuron Pharmaceuticals, Savara Pharmaceuticals, AMP Therapeutics, Hospira, Kasten, Madam Therapeutics, Phosphagenics, Pacgen Life Science Corporation.
The peptide antibiotics market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Peptide Antibiotics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Peptide Antibiotics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Peptide Antibiotics Market - Supply Chain
4.5. Global Peptide Antibiotics Market Forecast
4.5.1. Peptide Antibiotics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Peptide Antibiotics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Peptide Antibiotics Market Absolute $ Opportunity
5. Global Peptide Antibiotics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Peptide Antibiotics Market Size and Volume Forecast by Type
5.3.1. Ribosomal Synthesized Peptide Antibiotics
5.3.2. Non-Ribosomally Synthesized Peptide Antibiotics
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Peptide Antibiotics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Peptide Antibiotics Market Size and Volume Forecast by Application
6.3.1. Pharma & Healthcare
6.3.2. Food Industry
6.3.3. Commodities
6.3.4. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Peptide Antibiotics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Peptide Antibiotics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Peptide Antibiotics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Peptide Antibiotics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Peptide Antibiotics Demand Share Forecast, 2019-2026
9. North America Peptide Antibiotics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Peptide Antibiotics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Peptide Antibiotics Market Size and Volume Forecast by Application
9.4.1. Pharma & Healthcare
9.4.2. Food Industry
9.4.3. Commodities
9.4.4. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Peptide Antibiotics Market Size and Volume Forecast by Type
9.7.1. Ribosomal Synthesized Peptide Antibiotics
9.7.2. Non-Ribosomally Synthesized Peptide Antibiotics
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Peptide Antibiotics Demand Share Forecast, 2019-2026
10. Latin America Peptide Antibiotics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Peptide Antibiotics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Peptide Antibiotics Market Size and Volume Forecast by Application
10.4.1. Pharma & Healthcare
10.4.2. Food Industry
10.4.3. Commodities
10.4.4. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Peptide Antibiotics Market Size and Volume Forecast by Type
10.7.1. Ribosomal Synthesized Peptide Antibiotics
10.7.2. Non-Ribosomally Synthesized Peptide Antibiotics
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Peptide Antibiotics Demand Share Forecast, 2019-2026
11. Europe Peptide Antibiotics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Peptide Antibiotics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Peptide Antibiotics Market Size and Volume Forecast by Application
11.4.1. Pharma & Healthcare
11.4.2. Food Industry
11.4.3. Commodities
11.4.4. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Peptide Antibiotics Market Size and Volume Forecast by Type
11.7.1. Ribosomal Synthesized Peptide Antibiotics
11.7.2. Non-Ribosomally Synthesized Peptide Antibiotics
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Peptide Antibiotics Demand Share, 2019-2026
12. Asia Pacific Peptide Antibiotics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Peptide Antibiotics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Peptide Antibiotics Market Size and Volume Forecast by Application
12.4.1. Pharma & Healthcare
12.4.2. Food Industry
12.4.3. Commodities
12.4.4. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Peptide Antibiotics Market Size and Volume Forecast by Type
12.7.1. Ribosomal Synthesized Peptide Antibiotics
12.7.2. Non-Ribosomally Synthesized Peptide Antibiotics
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Peptide Antibiotics Demand Share, 2019-2026
13. Middle East & Africa Peptide Antibiotics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Peptide Antibiotics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Peptide Antibiotics Market Size and Volume Forecast by Application
13.4.1. Pharma & Healthcare
13.4.2. Food Industry
13.4.3. Commodities
13.4.4. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Peptide Antibiotics Market Size and Volume Forecast by Type
13.7.1. Ribosomal Synthesized Peptide Antibiotics
13.7.2. Non-Ribosomally Synthesized Peptide Antibiotics
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Peptide Antibiotics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Peptide Antibiotics Market: Market Share Analysis
14.2. Peptide Antibiotics Distributors and Customers
14.3. Peptide Antibiotics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Novartis
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GlaxoSmithKline
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Eli Lilly
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Theravance
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Vicuron Pharmaceuticals
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Savara Pharmaceuticals
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. AMP Therapeutics
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Hospira
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Kasten
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Madam Therapeutics
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Phosphagenics
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Pacgen Life Science Corporation
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
